Panitumumab-Induced Periorbital Dermatitis: A Case Report
Napapat Pongbangpho,Kumutnart Chanprapaph,Wimolsiri Iamsumang
DOI: https://doi.org/10.2147/ccid.s459067
2024-04-04
Clinical Cosmetic and Investigational Dermatology
Abstract:Napapat Pongbangpho, Kumutnart Chanprapaph, Wimolsiri Iamsumang Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Correspondence: Wimolsiri Iamsumang, Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajthevi, Bangkok, 10400, Thailand, Tel +662-201-1141, Fax +662-201-1211, Email Panitumumab is a recombinant, fully humanized immunoglobulin G 2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the first- and second-line treatment of advanced wild-type KRAS colorectal cancer. Although common cutaneous side effects include acneiform dermatitis, folliculitis, and xerosis, ocular toxicities have occasionally been reported. Herein, we report the case of an 81-year-old Thai female with chemorefractory advanced stage sigmoid colon cancer who developed isolated periorbital dermatitis following treatment with panitumumab plus modified FOLFOX6. The cutaneous adverse reaction recurred after subsequent infusions; however, it was alleviated by topical therapy. To our knowledge, panitumumab-induced periorbital dermatitis is exceptionally rare. To raise awareness of potential periocular cutaneous side effects in patients taking EGFR inhibitors, the published literature regarding periorbital dermatitis induced by these agents has also been reviewed in this article. Periorbital dermatitis should be considered as a potential cutaneous reaction following panitumumab administration, and should be promptly treated. Keywords: colorectal cancer, cutaneous adverse drug reaction, epidermal growth factor receptor inhibitors, panitumumab, periorbital rash Panitumumab is a recombinant, fully humanized immunoglobulin G 2 (IgG 2 ) monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the treatment of refractory metastatic wild-type Kirsten rat sarcoma virus (KRAS) colorectal cancer. 1 Panitumumab binds to the EGFR and interferes with downstream cell signaling, leading to the inhibition of cell growth and angiogenesis, and induces apoptosis. 2 Since EGFR is present on both normal epithelial cells and tumor cells, dermatological side effects, such as papulopustular eruptions, xerosis, and pruritus, are generally anticipated. 3 Similarly to other EGFR inhibitors, cutaneous toxicities are the most frequent adverse effect of panitumumab administration. 4,5 However, cases of panitumumab-induced periocular toxicity have scarcely been reported. We hereby present a rare case of panitumumab-induced periorbital dermatitis in a patient with advanced stage colorectal cancer. A literature review of periorbital dermatitis related to EGFR inhibitors is performed to emphasize this potential drug-related side effect. An 81-year-old female presented with significant weight loss and changes in bowel habit. Robot-assisted sigmoidectomy was carried out in April 2022 and the pathology report showed moderately differentiated adenocarcinoma with an absence of KRAS and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation. Clinical staging was performed and the diagnosis of sigmoid colon cancer stage IIIB (T4aN1M0) was established. She subsequently received eight cycles of capecitabine 3500 mg/day from June to November 2022. Unfortunately, she had progressive disease, with liver metastasis being detected on a computed tomography scan. In March 2023, the first cycle of modified FOLFOX6 (oxaliplatin 70 mg/m 2 , leucovorin 520 mg/m 2 , and fluorouracil 1200 mg/m 2 ) was commenced. Because of the disease progression, panitumumab 6 mg/kg had been added since the second cycle of chemotherapy, which was scheduled for administration every 2 weeks. In April 2023, after a week following the second cycle of the combination regimen, the patient developed periorbital skin erythema and pruritus, which spontaneously resolved within 1 week without treatment. Later on, after 10 days following the third cycle of panitumumab infusion, a similar periorbital rash occurred. She underwent a dermatological consultation and the physical examination revealed ill-defined scaly erythematous plaques with marked pruritus involving both periorbital areas (Figure 1A). She reported a history of using lubricant eye drops, which contained only hydroxypropyl methylcellulose, for several years, but denied the application of other ophthalmic medications or new facial skin care products. On ophthalmic evaluation, her corrected visual acuity was 20/30 and 20/50 in the right eye and the left eye, respectively. No papillary or follicular reactions were observed. Corneal examination showed minimal punctate epithelial erosions without epithelial defects. The slit-lamp examination r -Abstract Truncated-
dermatology